TRex Bio, Inc.
Sağlık
NOT REVIEWED — A definitive compliance result cannot be given for this company because one or more ratios could not be calculated.
$14.1
Price (1 Year)
Participation Finance Screening Ratios
Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.
About the Company
TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally. The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and treg function to identify and characterize therapeutic targets, using computational mapping, which uses in silico tools and a human tissue bank and atlas of human treg gene expression to identify pathways in tissue immune regulation; the Treg Atlas, which recreates tissue states in tregs and reprograms blood-derived Tregs to recreate human tissue-specific pathways in vitro for target validation; and the Phenotypic Assay Cascade, a suite of high-throughput functional fingerprinting assays that test targets across donors and inflammatory contexts.
Website